Dr. Manisha Shah on Cabozantinib Impact on Tumor Shrinkage in Differentiated Thyroid Cancer

Manisha Shah, MD, professor of Oncology, Ohio State University Medical Center, discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.

The study looked at 25 patients with radioiodine-refractory differentiated thyroid cancer who had progressed on prior VEGF receptor-targeted therapy. The study was designed with the goal of five out of the 25 patients achieving a partial response, explains Shah. However, the trial exceeded these expectations, with nine patients achieving significant tumor shrinkage and two other patients having some tumor shrinkage.

Based on these results, it appears that cabozantinib may be an effective second- or third-line therapy for patients with radioiodine-refractory differentiated thyroid cancer, says Shah.

<<<

View more from the 2015 International Thyroid Congress